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Background Exposure to anticholinergic and sedative drugs have
been associated with adverse health outcomes in the elderly popula-
tion, which can be measured in an individual patient using Drug
Burden Index (DBI). Higher DBI values were associated with poorer
cognitive and physical performance, which may negatively influence
cardiovascular disease (CVD) therapy outcomes.
Purpose The aim was to assess the anticholinergic and sedative drug
prevalence and burden in CVD patients.
Method A retrospective observational study was conducted on the
Cardiology ward of University Hospital Medical Center. Data were
collected from medical records. DBI was used to calculate the
exposure, based on the therapy used before the hospital admission.
Descriptive and statistical analysis was performed using IBM SPSS
Statistics ver. 22.
Findings A total of 254 patients aged C65 were included in the
analysis. Patients were comorbid (Charlson Comorbidity Index, mean
± S.D., 3.18 ± 1.63), with the average number of drugs above 6 (6.21
± 2.78). Anticholinergic or sedative drugs were used by 23 (9.1%)
patients, with identified 19 different drugs. The highest frequency was
observed for doxazosin (6; 2.4%), sertraline (6; 2.4%), memantine (4;
1.6%), clonazepam (3; 1.2%) and diazepam (3; 1.2%). The majority
of patients had only one drug (15; 5.9%), 2 patients (0.8%) used 2, 4
patients (1.6%) used 3, and 2 patients (0.8%) used 4 different drugs
with anticholinergic or sedative effects. Patients who were exposed to
those drugs had longer length of hospital stay (15.74 vs 9.41 days,
p\0.05), and higher total number of drugs (7.61 vs 6.07, p\0.05). The
average DBI value equalled 1.11 ± 0.74 (total range 0.33-2.60). DBI
\1 was present in 13 (5.1%) patients, and higher DBIC1 in 10 (4%)
patients.
Conclusion The study revealed lower than expected exposure to
anticholinergic or sedative drugs. The results could be seen as ben-
eficial, as the minimization of anticholinergic burden in CVD patients
is highly recommended.
Abstract number 412
Fall prevention and deprescribing of fall risk-increasing drugs:
the community pharmacists’ perspective
Marle Gemmeke1, Ellen S. Koster1, Eline A. Rodjik1, Katja
Taxis2, Marcel L. Bouvy1
1Division of Pharmacoepidemiology and Clinical Pharmacology,
Utrecht University. The Netherlands, 2Department of
Pharmacotherapy, Pharmacoepidemiology and Pharmacoeconomics
(PTEE), University of Groningen, The Netherlands. Email:
m.gemmeke@uu.nl
Background Pharmacists’ may contribute to fall prevention by
identifying and adjusting the use of fall risk-increasing drugs (FRIDs)
in patients with high fall risk. At the moment, pharmacists’ contri-
bution to fall prevention is poor. Presumably, pharmacists encounter
several barriers during the implementation of such services.
Purpose To explore community pharmacists’ barriers and facilitators
regarding provision of fall prevention care, specifically towards
deprescribing of FRIDs.
Method A mixed-method study was conducted, consisting of quan-
titative (ranking statements, survey) and qualitative data (semi-
structured interviews) with Dutch pharmacists. Quantitative data were
analysed using descriptive statistics. All interviews were audiotaped
and transcribed verbatim. The capability opportunity motivation –
behaviour (COM-B) system was applied to interpret the findings.
Findings In total, 313 Dutch pharmacists ranked statements during an
interactive presentation, 205 of them completed a survey and 16 were
interviewed. Pharmacists were motivated and confident about their
potential in fall prevention care. Their capability to provide fall
prevention care included mainly the deprescribing of FRIDs. How-
ever, their self-reported current contribution was poor. Major barriers
with regard to opportunity were identified, including insufficient
multidisciplinary collaboration and patient unwillingness to depre-
scribe FRIDs.
Conclusion Community pharmacists are motivated to provide fall
prevention services, particularly deprescribing of FRIDs. They
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